VIDA Insights

VIDA

VIDA Insights™ is a lung intelligence solution providing quantitative data and visualizations. VIDA’s biomarkers measure lung destruction, inflammation, function and more, to aid the detection, diagnosis, treatment and tracking of all major lung diseases, including COPD, ILD and now COVID-19.
Product specifications Information source: Vendor
Last updated: Feb. 28, 2020
General
Product name VIDA Insights
Company VIDA
Subspeciality Chest
Modality CT
Disease targeted COPD, interstitial lung disease (ILD), emphysema, COVID-19
Key-features Lung disease biomarkers, lung (lobe) volume quantification, scan suitability quality check, Hyperion View (tMPR), low density tissue quantification by lobe, high density tissue quantification by lobe, trachea analysis and quanitification
Suggested use Before: stratifying reading process (non, single, double read)
During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion
Data characteristics
Population All Chest CT scans
Input Non-contrast
Input format DICOM
Output Quantified Values, Novel Visualizations, Quick Flag Diagrams
Output format DICOM SC
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis Automatically, right after the image acquisition
Processing time 1 - 10 minutes
Certification
CE
Certified, Class IIa
FDA
510(k) cleared, Class II
Market presence
On market since 12-2019
Distribution channels Nuance, Eureka Clinical AI, TeraRecon, IBM Watson Health, Blackford, Intelerad
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Subscription
Based on Total imaging volume
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers

  • Relationships Between Airflow Obstruction and Quantitative CT Measurements of Emphysema, Air Trapping, and Airways in Subjects With and Without Chronic Obstructive Pulmonary Disease (read)

  • Quantitative computed tomography of the lungs and airways in healthy nonsmoking adults (read)

  • Total Airway Count on Computed Tomography and the Risk of Chronic Obstructive Pulmonary Disease Progression. Findings from a Population-based Study (read)

  • Quantitative CT of Interstitial Lung Disease (read)

  • SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs (read)